CA Patent

CA2902343C — Injectable morphine formulations

Assigned to Fresenius Kabi Deutschland GmbH · Expires 2022-08-02 · 4y expired

What this patent protects

Provided herein, generally, are pharmaceutical formulations, e.g., injectable pharmaceutical formulations with improved stability, comprising morphine sulfate or a hydrate thereof, and methods of producing and using the same. Also provided herein are kits comprising the formulati…

USPTO Abstract

Provided herein, generally, are pharmaceutical formulations, e.g., injectable pharmaceutical formulations with improved stability, comprising morphine sulfate or a hydrate thereof, and methods of producing and using the same. Also provided herein are kits comprising the formulations, e.g., injectable morphine formulations.

Drugs covered by this patent

Patent Metadata

Patent number
CA2902343C
Jurisdiction
CA
Classification
—
Expires
2022-08-02
Drug substance claim
No
Drug product claim
No
Assignee
Fresenius Kabi Deutschland GmbH
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.